FDA Approves Lamisil for the Treatment of Scalp Ringworm in Children

The United States Food and Drug Administration recently approved the medication Lamisil for the treatment of tinea capitis, a fungal infection of the scalp.

Tinae capitis otherwise, more commonly known as, ringworm of the scalp is most commonly seen among children aged four years old and older. The fungal infection is caused by dermatophytes, a mold-like fungi. These fungi grow in moist, warm areas, and children are at increased risk for developing scalp ringworm if they incur scalp injuries sweat a lot, and/or possess poor hygiene.

Ringworm of the scalp is contagious; it can be spread by touching an infected person's clothes, comb or brush, hat, or other items or by direct contact with an infected person. Pets, especially cats, can also spread the infection.

Tinae capitis does not generally respond to topical solutions.

The FDA has recently approved the medication Lamisil for the treatment of scalp ringworm in children. The medication is available in granules, which allow it to be sprinkled on top of food, which is particularly advantageous for children who do not like to or cannot swallow pills.

Lamisil is an antifungal medication which is also often used to treat fungal infections of the toenails and fingernails.

Lamisil may cause side-effects including nausea, a loss of taste, diarrhea, and/or headaches. Rash, swelling of the lips, face, tongue, and/or throat, hives, and/or changes in vision are signs of an allergic reaction, and one should contact their child's doctor immediately if a child taking Lamisil experiences these side-effects.

Abdominal pain, unusual fatigue, vomiting, dark urine, clay colored stools, yellow eyes or skin, and/or loss of appetite may be early signs of liver failure, which is a rare side-effect of this medication.